BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...